Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis

Douglas M. Watts, Robert B. Tesh, Marina Siirin, Amelia Travassos da Rosa, Patrick C. Newman, David E. Clements, Steven Ogata, Beth Ann Coller, Carolyn Weeks-Levy, Michael M. Lieberman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The efficacy of a new recombinant subunit West Nile virus (WNV) vaccine candidate was determined in a hamster model of meningoencephalitis. Groups of hamsters were immunized subcutaneously with a WNV recombinant envelope protein (80E) with or without WNV non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. At 2 weeks, 6 months, and 12 months after two immunizations at 4 week intervals with the respective immunogens, groups of animals were challenged via the intraperitoneal route with a virulent strain of WNV. The two recombinant antigen preparations gave similar results; hamsters in both groups had a strong antibody response following immunization, and none of the animals became ill or developed detectable viremia after challenge with WNV at 2 weeks or 6 months post-booster vaccination. In contrast, mortality among the control animals at 2 weeks post-booster challenge was 73%, and at 6 months post-booster, the mortality was 53% among the control animals. When challenged 12 months after the booster vaccination, a low level viremia was detected in some of the vaccinated hamsters, and one hamster became sick, but recovered. In contrast, all of the control animals that received adjuvant only developed a viremia, and the mortality rate was 77%. These results with the recombinant subunit WNV vaccine are very encouraging and warrant further animal studies to evaluate its potential use to protect humans against WNV disease.

Original languageEnglish (US)
Pages (from-to)2913-2918
Number of pages6
JournalVaccine
Volume25
Issue number15
DOIs
StatePublished - Apr 12 2007

Fingerprint

West Nile virus
Encephalitis
durability
encephalitis
hamsters
Cricetinae
Vaccines
vaccines
West Nile Virus Vaccines
Viremia
viremia
Subunit Vaccines
adjuvants
animals
Mortality
Immunization
Vaccination
immunization
Viral Envelope Proteins
Viral Structural Proteins

Keywords

  • Protection of hamsters against West Nile virus encephalitis
  • West Nile virus recombinant subunit vaccine
  • West Nile virus vaccine protective efficacy

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Watts, D. M., Tesh, R. B., Siirin, M., Rosa, A. T. D., Newman, P. C., Clements, D. E., ... Lieberman, M. M. (2007). Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine, 25(15), 2913-2918. https://doi.org/10.1016/j.vaccine.2006.08.008

Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. / Watts, Douglas M.; Tesh, Robert B.; Siirin, Marina; Rosa, Amelia Travassos da; Newman, Patrick C.; Clements, David E.; Ogata, Steven; Coller, Beth Ann; Weeks-Levy, Carolyn; Lieberman, Michael M.

In: Vaccine, Vol. 25, No. 15, 12.04.2007, p. 2913-2918.

Research output: Contribution to journalArticle

Watts, DM, Tesh, RB, Siirin, M, Rosa, ATD, Newman, PC, Clements, DE, Ogata, S, Coller, BA, Weeks-Levy, C & Lieberman, MM 2007, 'Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis', Vaccine, vol. 25, no. 15, pp. 2913-2918. https://doi.org/10.1016/j.vaccine.2006.08.008
Watts, Douglas M. ; Tesh, Robert B. ; Siirin, Marina ; Rosa, Amelia Travassos da ; Newman, Patrick C. ; Clements, David E. ; Ogata, Steven ; Coller, Beth Ann ; Weeks-Levy, Carolyn ; Lieberman, Michael M. / Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. In: Vaccine. 2007 ; Vol. 25, No. 15. pp. 2913-2918.
@article{91c33be0852341ecbd7f4684d518e6d0,
title = "Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis",
abstract = "The efficacy of a new recombinant subunit West Nile virus (WNV) vaccine candidate was determined in a hamster model of meningoencephalitis. Groups of hamsters were immunized subcutaneously with a WNV recombinant envelope protein (80E) with or without WNV non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. At 2 weeks, 6 months, and 12 months after two immunizations at 4 week intervals with the respective immunogens, groups of animals were challenged via the intraperitoneal route with a virulent strain of WNV. The two recombinant antigen preparations gave similar results; hamsters in both groups had a strong antibody response following immunization, and none of the animals became ill or developed detectable viremia after challenge with WNV at 2 weeks or 6 months post-booster vaccination. In contrast, mortality among the control animals at 2 weeks post-booster challenge was 73{\%}, and at 6 months post-booster, the mortality was 53{\%} among the control animals. When challenged 12 months after the booster vaccination, a low level viremia was detected in some of the vaccinated hamsters, and one hamster became sick, but recovered. In contrast, all of the control animals that received adjuvant only developed a viremia, and the mortality rate was 77{\%}. These results with the recombinant subunit WNV vaccine are very encouraging and warrant further animal studies to evaluate its potential use to protect humans against WNV disease.",
keywords = "Protection of hamsters against West Nile virus encephalitis, West Nile virus recombinant subunit vaccine, West Nile virus vaccine protective efficacy",
author = "Watts, {Douglas M.} and Tesh, {Robert B.} and Marina Siirin and Rosa, {Amelia Travassos da} and Newman, {Patrick C.} and Clements, {David E.} and Steven Ogata and Coller, {Beth Ann} and Carolyn Weeks-Levy and Lieberman, {Michael M.}",
year = "2007",
month = "4",
day = "12",
doi = "10.1016/j.vaccine.2006.08.008",
language = "English (US)",
volume = "25",
pages = "2913--2918",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15",

}

TY - JOUR

T1 - Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis

AU - Watts, Douglas M.

AU - Tesh, Robert B.

AU - Siirin, Marina

AU - Rosa, Amelia Travassos da

AU - Newman, Patrick C.

AU - Clements, David E.

AU - Ogata, Steven

AU - Coller, Beth Ann

AU - Weeks-Levy, Carolyn

AU - Lieberman, Michael M.

PY - 2007/4/12

Y1 - 2007/4/12

N2 - The efficacy of a new recombinant subunit West Nile virus (WNV) vaccine candidate was determined in a hamster model of meningoencephalitis. Groups of hamsters were immunized subcutaneously with a WNV recombinant envelope protein (80E) with or without WNV non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. At 2 weeks, 6 months, and 12 months after two immunizations at 4 week intervals with the respective immunogens, groups of animals were challenged via the intraperitoneal route with a virulent strain of WNV. The two recombinant antigen preparations gave similar results; hamsters in both groups had a strong antibody response following immunization, and none of the animals became ill or developed detectable viremia after challenge with WNV at 2 weeks or 6 months post-booster vaccination. In contrast, mortality among the control animals at 2 weeks post-booster challenge was 73%, and at 6 months post-booster, the mortality was 53% among the control animals. When challenged 12 months after the booster vaccination, a low level viremia was detected in some of the vaccinated hamsters, and one hamster became sick, but recovered. In contrast, all of the control animals that received adjuvant only developed a viremia, and the mortality rate was 77%. These results with the recombinant subunit WNV vaccine are very encouraging and warrant further animal studies to evaluate its potential use to protect humans against WNV disease.

AB - The efficacy of a new recombinant subunit West Nile virus (WNV) vaccine candidate was determined in a hamster model of meningoencephalitis. Groups of hamsters were immunized subcutaneously with a WNV recombinant envelope protein (80E) with or without WNV non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. At 2 weeks, 6 months, and 12 months after two immunizations at 4 week intervals with the respective immunogens, groups of animals were challenged via the intraperitoneal route with a virulent strain of WNV. The two recombinant antigen preparations gave similar results; hamsters in both groups had a strong antibody response following immunization, and none of the animals became ill or developed detectable viremia after challenge with WNV at 2 weeks or 6 months post-booster vaccination. In contrast, mortality among the control animals at 2 weeks post-booster challenge was 73%, and at 6 months post-booster, the mortality was 53% among the control animals. When challenged 12 months after the booster vaccination, a low level viremia was detected in some of the vaccinated hamsters, and one hamster became sick, but recovered. In contrast, all of the control animals that received adjuvant only developed a viremia, and the mortality rate was 77%. These results with the recombinant subunit WNV vaccine are very encouraging and warrant further animal studies to evaluate its potential use to protect humans against WNV disease.

KW - Protection of hamsters against West Nile virus encephalitis

KW - West Nile virus recombinant subunit vaccine

KW - West Nile virus vaccine protective efficacy

UR - http://www.scopus.com/inward/record.url?scp=33947157608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947157608&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.08.008

DO - 10.1016/j.vaccine.2006.08.008

M3 - Article

VL - 25

SP - 2913

EP - 2918

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15

ER -